Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

This publication has 14 references indexed in Scilit:

• Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
  Blood, 2024
• Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
  The Lancet Haematology, 2024
• MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients
  Annals of Hematology, 2024
• Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
  Blood Cancer Journal, 2024
• Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
  American Journal of Hematology, 2023
• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
  The Lancet, 2023
• Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
  British Journal of Haematology, 2021
• Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
  The Lancet Haematology, 2018
• Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
  Blood, 2017
• Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
  Blood, 2013